You are here: Home: PCU Think Tank 1 | 2006: Section 3: Select Publications

Select Publications

Arlen PM et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12(4):1260-9. Abstract

Beer TM et al. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2003;89(6):968-70. Abstract

Beer TM et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21(1):123-8. Abstract

Berry DL et al. Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006;24(18):2828-35. Abstract

Berthold DR et al. Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. Proc ASCO 2006;Abstract 4516.

Caffo O et al. A multicentric phase II randomized trial of docetaxel (D) plus estramustine (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC). Proc ASCO 2006;Abstract 4625.

Chan JS et al. Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT. Proc ASCO 2006;Abstract 4614.

Ferrero JM et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 2006;107(4):738-45. Abstract

Lucas A, Petrylak DP. The case for early chemotherapy for the treatment of metastatic disease. J Urol 2006;176(6 Pt 2):S72-5. Abstract

Oudard S et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23(15):3343-51. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Home